Skip to main content
. 2020 Jul 24;6:31. doi: 10.1038/s41523-020-00174-9

Fig. 1. Tumor marker response to olaparib.

Fig. 1

Compared with pretreatment levels, there was a marked reduction in circulating CA 15–3 at 3 months after initiation of olaparib, which was deepened and sustained after 8 months of treatment.